ArticleActa oncologica (Stockholm, Sweden)2026
The role of radiotherapy in patients with advanced melanoma failing targeted therapy.
Article in Acta oncologica (Stockholm, Sweden), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeApproximately 50% of patients with metastatic melanoma harbor mutations in the BRAF gene, making them eligible for targeted therapy (TT). However, treatment options become limited once resistance develops. The role of radiotherapy (RT) in this context remains uncertain, and concerns exist regarding toxicity when RT is delivered concurrently with TT. Patient/material and methods: This retrospective study included metastatic melanoma patients treated with RT after experiencing disease progressing on TT between 2015 and 2023. Patients were grouped by subsequent systemic therapy: RT-STOP (discontinued TT), RT-TT (continued TT), and RT-ICI (switched to immune checkpoint inhibitors (ICI)). Study endpoints were progression-free survival (PFS), overall survival (OS), efficacy, and toxicity.
resultsSixty-three patients were analyzed. Median PFS and OS were 1.9 and 3.1 months. The median OS in RT-STOP, RT-TT, and RT-ICI was 1.7, 4.7, and 3.0 months, while the 1-year OS rate was 4.9, 7.6, and 33.4%, respectively (p = 0.001). RT was well tolerated, with no grade ≥3 adverse events observed and 50.9% of patients derived a local benefit.
interpretationIn advanced melanoma patients with disease progression on TT, RT was safe and provided a local effect. Although survival outcomes remained suboptimal, continuation of TT beyond progression or transition to ICI following RT was associated with improved OS compared with discontinuation of TT. These results support the role of RT as a safe bridging modality, suggest benefit from treatment beyond progression with TT, and warrant confirmation in prospective trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.